Skip to main content

Lilly's rheumatoid arthritis drug shortens Covid-19 hospitalization when combined with antiviral med

By Forbes  
   September 15, 2020

Eli Lilly and Company announced Monday morning that a study conducted by (NIAID of hospitalized Covid-19 patients found that its rheumatoid arthritis drug baricitinib, in combination with Gilead's antiviral drug remdesivir, reduces the median hospital stay of patients by one day compared to treatment with remdesivir alone.

Full story

Get the latest on healthcare leadership in your inbox.